Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Keyphrases

• Adult Case 25%
• Adverse Events 25%
• Amoxicillin 25%
• Bismuth 25%
• Bismuth Quadruple Therapy 25%
• Clarithromycin 25%
• Cure Rate 25%
• Data Monitoring 25%
• Data Quality 25%
• Dose Duration 25%
• Duration of Therapy 25%
• Electronic Data Capture 25%
• Empirical Therapy 25%
• Eradication Rate 50%
• Eradication Therapy 25%
• Europe 25%
• European Registries 100%
• Gastroenterologist 25%
• Helicobacter Pylori (H. pylori) 100%
• Helicobacter Pylori Eradication 25%
• High Dose 25%
• Hospitalization 25%
• Hp-EuReg 100%
• Intention-to-treat Analysis 25%
• Levofloxacin 75%
• Modified Intention-to-treat 25%
• Moxifloxacin 50%
• Non-interventional 25%
• Overall Effectiveness 25%
• Patient's Will 25%
• Penicillin 25%
• Per-protocol 25%
• Proton Pump Inhibitors 50%
• Quadruple Therapy 100%
• Quinolones 25%
• Second-line Therapy 100%
• Second-line Treatment 75%
• Serious Adverse Events 25%
• Susceptibility-guided Therapy 25%
• Triple Therapy 100%

Medicine and Dentistry

• Adverse Event 66%
• Amoxicillin 33%
• Clarithromycin 33%
• Drug Megadose 33%
• Helicobacter Pylori 100%
• Intention-to-Treat Analysis 33%
• Levofloxacin 100%
• Moxifloxacin 66%
• Penicillin Derivative 33%
• Proton-Pump Inhibitor 66%
• Pylorus 33%
• Quinolone 33%
• Treatment Duration 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 66%
• Amoxicillin 33%
• Clarithromycin 33%
• Helicobacter Pylori 100%
• Levofloxacin 100%
• Moxifloxacin 66%
• Penicillin Derivative 33%
• Proton Pump Inhibitor 66%
• Quinolone 33%